Literature DB >> 26291542

One-Legged Cycle Training for Chronic Obstructive Pulmonary Disease. A Pragmatic Study of Implementation to Pulmonary Rehabilitation.

Rachael A Evans1,2,3, Thomas E Dolmage1,4, Suzanna Mangovski-Alzamora1, Julia Romano1, Lauren O'Brien1,3, Dina Brooks1,5, Roger S Goldstein1,4,3,5.   

Abstract

RATIONALE: In patients with chronic obstructive pulmonary disease (COPD), partitioned exercise training using one-legged cycling leads to greater improvements in peak oxygen uptake than conventional two-legged cycling.
OBJECTIVES: We evaluated the feasibility of incorporating one-legged cycling as the principal aerobic training modality for pulmonary rehabilitation in COPD.
METHODS: Physiotherapists underwent four teaching sessions about the principles and practical implementation of one-legged cycling training. Patients enrolled in a pulmonary rehabilitation program underwent 6-8 weeks of training in which one-legged cycling three times per week was the principal aerobic exercise activity. Participants cycled for 15 minutes with each leg, in each session. An incremental cardiopulmonary exercise test was completed before and after pulmonary rehabilitation along with standard pulmonary rehabilitation outcome measures. Participants and physiotherapists completed a satisfaction survey at the end of the program.
MEASUREMENTS AND MAIN RESULTS: A total of 22 out of 32 participants (14 male; mean [SD] age, 66 [7] years; FEV1% predicted, 32 [17]%; median [interquartile range] Medical Research Council dyspnea scale, 3.5 [3.0-4.3]) completed pulmonary rehabilitation. Peak oxygen uptake increased 1.1 (0.4-1.7) ml·min(-1)·kg(-1) (8%) from baseline (P<0.01). The mean (95% confidence interval) 6-minute-walk test distance improved by 72 (45-98) m (P=0.001). The change in the Chronic Respiratory Questionnaire total score of 1.6 (1.1-2.1; P<0.001) was achieved by improvement in all four domains above the clinically important difference. All the physiotherapists considered one-legged cycling safe and would continue to prescribe it; 75% of participants would recommend it to other patients.
CONCLUSIONS: One-legged cycling was successfully implemented into a "real-life" pulmonary rehabilitation program, demonstrating improvements in cardiorespiratory fitness with associated improvement in function for patients with moderate/severe COPD. One-legged cycling should be recommended in professional pulmonary rehabilitation guidelines as an option for exercise training and be available in other pulmonary rehabilitation programs. Clinical trial registered with www.clinicaltrials.gov (NCT01930526).

Entities:  

Keywords:  human; lung diseases; muscle; obstructive; oxygen consumption; physical conditioning; pulmonary; rehabilitation; skeletal

Mesh:

Year:  2015        PMID: 26291542     DOI: 10.1513/AnnalsATS.201504-231OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  4 in total

1.  Cardiorespiratory Responses between One-legged and Two-legged Cycling in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Thomas E Dolmage; Tom Reilly; Neil J Greening; Sally Majd; Bhavesh Popat; Sanjay Agarwal; Felix A Woodhead; Rachael A Evans
Journal:  Ann Am Thorac Soc       Date:  2020-02

2.  Physiological responses to incremental, interval, and continuous counterweighted single-leg and double-leg cycling at the same relative intensities.

Authors:  Martin J MacInnis; Nathaniel Morris; Michael W Sonne; Amanda Farias Zuniga; Peter J Keir; Jim R Potvin; Martin J Gibala
Journal:  Eur J Appl Physiol       Date:  2017-05-11       Impact factor: 3.078

3.  Role of progression of training volume on intramuscular adaptations in patients with chronic obstructive pulmonary disease.

Authors:  Andre Nyberg; Nadia Milad; Mickael Martin; Dany Patoine; Mathieu C Morissette; Didier Saey; François Maltais
Journal:  Front Physiol       Date:  2022-08-23       Impact factor: 4.755

Review 4.  Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications For Real-Life Performance and Rehabilitation.

Authors:  Mathieu Gruet
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.